Cencora

(New York Stock Exchange)
Back to all articles
Bullish +75

Argus raises target for Cencora stock to USD 380.00

Acquisition Analyst upgrade AI-generated analysis

πŸ“ˆ Argus Capital raised its price target for Cencora stock from USD 340.00 to USD 380.00 on October 20, 2026.

πŸ’° Cencora agreed to acquire American Oncology Network for a total transaction value of USD 2.4 billion on October 21, 2026.

πŸ“Š The company reported Q3 fiscal 2026 revenue of USD 84.75 billion, representing a 5.1% year-over-year increase.

πŸš€ Cencora lifted its fiscal 2026 adjusted diluted earnings per share floor to USD 17.90 on October 22, 2026.

πŸ“… The company is scheduled to release fourth-quarter fiscal 2026 results before the NYSE opens on November 4, 2026.

πŸ₯ American Oncology Network includes more than 350 oncology providers across 21 states in the United States.

πŸ’΅ The acquisition of AON is expected to contribute to adjusted diluted earnings per share in the second year after closing.

πŸ“‰ Cencora stock traded at EUR 296.35 on October 27, 2026, slightly below the previous Xetra close.

🏒 The company operates in the Healthcare and Medical Distribution sector with a market capitalization of USD 63.1 billion.

Bullish Signals
  • Argus Capital raised its price target for Cencora stock from USD 340.00 to USD 380.00, reflecting positive analyst sentiment regarding the company's valuation.
  • Cencora successfully reported Q3 fiscal 2026 revenue of USD 84.75 billion, achieving a 5.1% year-over-year growth rate.
  • The company beat earnings expectations with adjusted diluted EPS of USD 4.48 against a consensus estimate of USD 4.35 in the third quarter.
  • Cencora lifted its fiscal 2026 adjusted diluted earnings per share guidance floor to USD 17.90, demonstrating strong operational performance.
  • The acquisition of American Oncology Network is projected to add to adjusted diluted earnings per share in the second year post-closing.
  • Cencora secured a strategic agreement to acquire a physician-led network with over 350 oncology providers across 21 states for USD 2.4 billion.
Full Analysis
Argus Capital raised its price target for Cencora Inc. (COR) from USD 340.00 to USD 380.00 on October 20, 2026, signaling increased analyst confidence in the company's valuation and growth prospects. This bullish adjustment comes amidst a period of significant strategic expansion and strong financial performance for the healthcare distribution giant. Cencora recently announced a major acquisition agreement to purchase American Oncology Network (AON) for USD 2.4 billion on October 21, 2026. The deal includes contingent value rights of up to USD 100 million and is expected to add to adjusted diluted earnings per share in the second year following closing, subject to regulatory approvals. The company reported robust third-quarter fiscal 2026 results with revenue reaching USD 84.75 billion, a 5.1% increase year over year. Additionally, Cencora lifted its full-year adjusted diluted earnings per share guidance floor to USD 17.90 on October 22, 2026, indicating strong operational execution and confidence in future profitability.